Syndax Pharmaceuticals Inc (SNDX) reports promising revenue from Revv Forge launch and outlines strategic growth plans, ...

HC Wainwright restated their buy rating on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a report published ...

Analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for shares of Syndax Pharmaceuticals in a ...

About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj ® ...

Highlights,Target price adjustments for Syndax Pharmaceuticals reflect varied market sentiment.,Executive decisions on stock ...

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today ...

Barclays analyst Peter Lawson maintained a Buy rating on Immunocore Holdings (IMCR – Research Report) today and set a price target of $66.00.

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today ...

WALTHAM, Mass. - Syndax Pharmaceuticals (NASDAQ:SNDX), a developer of cancer therapies, today announced the immediate appointment of Steven Closter as Chief ...

Investing.com – U.S. stocks were lower after the close on Tuesday, as losses in the Healthcare, Technology and Consumer Services sectors led shares lower. At the close in NYSE,... Top Gainers ...

After hours: March 7 at 6:38:22 p.m. EST Loading Chart for SNDX ...